CAMBRIDGE, Mass. & OSAKA, Japan, December 8, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a media advisory call to hear Takeda business executives and scientific leadership provide updates on several of the 12 unique New Molecular Entities (NMEs) in the Wave 1 pipeline portfolio, which represent potential best-in-class / first-in-class therapies targeted for launch by FY2024 with aggregate potential peak sales of more than $10 billion. With seven of these potential Wave 1 NME filings expected in the next 12 months, as well as room for additional expansions of our existing 14 global brands, Takeda is well positioned for organic and sustainable revenue growth in the coming years.
December 8, 2020
5:00 p.m. – 7:15 p.m. EST / 7:00 a.m. – 9:15 a.m. JST
Takeda has built a world-class R&D engine leveraging internal research capabilities, while also actively engaging with innovative ecosystems around the world to translate science into highly innovative life-changing medicines.
Takeda business executives and scientific leadership will provide updates on several of the 12 unique New Molecular Entities (NMEs) in Wave 1 of Takeda’s pipeline portfolio, which represent potential best-in-class / first-in-class therapies targeted for launch by FY2024 with aggregate potential peak sales of more than $10 billion. With seven of these potential Wave 1 NME filings expected in the next 12 months, as well as room for additional expansions of our existing 14 global brands, Takeda is well positioned for organic and sustainable revenue growth in the coming years.
Email firstname.lastname@example.org to RSVP and receive call information. There will be a Q&A session at the end with speakers. If you wish to ask questions, please share those in advance.
The agenda for Takeda’s call is as follows:
|TIME (EST)||TIME (JST)||Session/Speaker|
|5:00 p.m. – 5:10 p.m.||7:00 a.m. – 7:10 a.m.||
Takeda – A Global Values-Based, R&D-Driven Biopharmaceutical Leader
|5:10 p.m. – 5:25 p.m.||7:10 a.m. – 7:25 a.m.||
Following Through on Our Commitment to Deliver Innovative Medicines to Patients: Spotlight on Select Wave 1 Programs
|5:25 p.m. – 5:35 p.m.||7:25 a.m. – 7:35 a.m.||
Entyvio® Case Study: Building a Gold Standard Along the Patient Journey
|5:35 p.m. – 6:05 p.m.||7:35 a.m. – 8:05 a.m.||
TAK-721 Deep Dive: Potential to be First FDA-Approved Agent with Indication Eosinophilic Esophagitis
|6:05 p.m. – 6:35 p.m.||8:05 a.m. – 8:35 a.m.||
TAK-003 Deep Dive: Live Attenuated Tetravalent Vaccine for Prevention of Dengue Disease
|6:35 p.m. – 7:15 p.m.||8:35 a.m. – 9:15 a.m.||Panel Q&A Session|
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced, collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com.
Japanese Media Media outside Japan
Kazumi Kobayashi Holly Campbell
+81 (0) 3-3278-2095 +1 (617) 588-9013
For the purposes of this notice, “media alert” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This media alert (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this media alert. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This media alert is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this media alert, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This media alert and any materials distributed in connection with this media alert may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this media alert or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this media alert may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.